Milestone Pharmaceuticals Inc. (MIST): Insider Trading, Congress Trades & Research | Tormere

MIST

$0.76+5.30%visit website

Milestone Pharmaceuticals Inc.

Market Cap

$95M

Live price × SEC shares (Aug 12, 2026)

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

1.06

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

5.2

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

N/M

TTM to Jun 2026 · negative EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue			238	559
Cost of revenue			14.0	32.0
Research & development	3,940	5,521	3,251	3,509	16,221
Selling, general & administrative				22,648
Operating income	(11,829)	(17,257)	(23,663)	(25,630)	(78,379)
Interest expense	967	985	4,135	4,725	10,812
Net income	(11,922)	(17,409)	(26,066)	(28,614)	(84,011)
EPS (basic) ($)	(0.12)		(0.20)	(0.21)	—
EPS (diluted) ($)	(0.12)		(0.20)	(0.21)	—

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 12, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 30 more quarters, back to Mar 2018, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

Analyst Consensus

Strong Buy

13 analysts

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-04-16	2026-04-20	Oliveto Joseph	Director & President and CEO	Sale	36.5K	$2.26	$82K	446.2K	View

Recent News

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo Finance · 2026-11-04

Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026

Yahoo · 2026-11-03

A heart-medicine developer, Milestone Pharmaceuticals, will report Q3 results Nov. 13 and host an 8:30 a.m. call.

Stock Titan · 2026-11-03

New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation

Yahoo · 2026-11-02

Has Milestone Pharmaceuticals (NASDAQ:MIST) penny stock rebounded pre-market following its Nasdaq bid price warning?

Kalkine · 2026-11-02

Milestone Pharmaceuticals Inc. Estimates – NASDAQ:MIST

TradingView · 2026-10-25

Milestone Pharmaceuticals (MIST) Stock Sees Fair Value Falls As Analysts Reset Cardamyst Expectations

Yahoo · 2026-10-23

Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences

Yahoo · 2026-10-19

Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial

Yahoo · 2026-10-09

Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR

Yahoo Finance · 2026-09-24

Milky Mist shares surge over 100% since August IPO: What comes next?

Investing.com · 2026-09-11

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States

Yahoo Finance · 2026-09-03

Milestone Pharmaceuticals: Reiterating Sell As The Losses Compound (NASDAQ:MIST)

Seeking Alpha · 2026-08-18

Milestone Pharmaceuticals Q2 Earnings Call Highlights

Yahoo Finance · 2026-08-12

Milestone Pharmaceuticals shares tumble after Q2 earnings miss

Yahoo Finance · 2026-08-12

Informational purposes only, not investment advice.

Corporate Events (8-K)

11 filings in 12 months · 1 with priority itemsFull history →

Filed	Items	Filing
Oct 28, 2026 accepted 5:00 PM ET	3.01Delisting notice	Document SEC ↗
Sep 3, 2026 accepted 4:03 PM ET	8.01Other events	Document SEC ↗
Aug 12, 2026 accepted 7:28 AM ET	2.02Earnings release	Document SEC ↗
Jun 15, 2026 accepted 4:05 PM ET	5.02Officer / director change5.07Shareholder vote	Document SEC ↗
May 13, 2026 accepted 7:23 AM ET	2.02Earnings release	Document SEC ↗
Mar 20, 2026 accepted 7:25 AM ET	2.02Earnings release	Document SEC ↗
Jan 26, 2026 accepted 9:27 AM ET	8.01Other events	Document SEC ↗
Jan 13, 2026 accepted 6:06 AM ET	8.01Other events	Document SEC ↗
Jan 6, 2026 accepted 8:05 AM ET	8.01Other events	Document SEC ↗
Dec 15, 2025 accepted 8:56 AM ET	7.01Reg FD disclosure8.01Other events	Document SEC ↗